FDA & ICH M15 Guidance 2026: Complete Guide To Model-Informed Drug Development (MIDD) For Regulatory Decision-Making

Understanding the New Harmonized Framework for Modeling & Simulation, Regulatory Evidence Generation, and Drug Development Strategy

The pharmaceutical industry is increasingly relying on advanced modeling and simulation approaches to support critical development and regulatory decisions.

From dose selection and clinical trial optimization to benefit-risk assessments and label claims, Model-Informed Drug Development (MIDD) has evolved from a specialized scientific discipline into a core component of modern drug development.

Recognizing the growing importance of MIDD, the International Council for Harmonization (ICH) finalized the M15 Guideline at Step 4 in January 2026, with publication by the U.S. Food and Drug Administration (FDA) in June 2026.

The guidance establishes the first globally harmonized framework for planning, evaluating, documenting, and assessing MIDD evidence intended to support regulatory decision-making.

For sponsors, regulatory affairs professionals, clinical pharmacologists, modelers, and drug developers, understanding the new expectations is essential for successful global submissions.

Failure to adequately plan and evaluate MIDD activities may result in:

• Regulatory review delays
• Additional information requests
• Reduced confidence in model outputs
• Challenges in supporting development decisions
• Increased submission complexity
• Inconsistent regulatory acceptance
• Extended development timelines
• Increased development costs

As regulators increasingly embrace quantitative evidence, organizations must ensure that their modeling strategies align with evolving international expectations.

Executive Overview

ICH M15 establishes a risk-informed and fit-for-purpose framework for generating and evaluating evidence derived from modeling and simulation (M&S).

The guideline applies across the drug development lifecycle and supports the use of quantitative approaches in regulatory submissions.

Key Objectives of ICH M15

The framework is built around six foundational elements that determine how MIDD evidence should be evaluated and utilized.

These include:

• Question of Interest
• Context of Use
• Model Influence
• Consequence of Wrong Decision
• Model Risk
• Model Impact

Together, these elements create a structured methodology for assessing the credibility and regulatory relevance of modeling evidence.

Why Model-Informed Drug Development Matters More Than Ever

Drug development continues to become more complex.

Sponsors increasingly face challenges involving:

• Diverse patient populations
• Rare diseases
• Accelerated approval pathways
• Precision medicine approaches
• Global development programs
• Limited clinical data availability

Modeling and simulation approaches help organizations:

• Optimize clinical development plans
• Support dose justification
• Predict clinical outcomes
• Evaluate exposure-response relationships
• Inform trial design decisions
• Support regulatory interactions

As regulatory agencies become more comfortable with quantitative evidence, MIDD is evolving into a strategic development capability rather than a supplementary analytical tool.

Regulatory readiness is becoming a competitive advantage.

Understanding ICH M15

ICH M15 provides principles for the generation, evaluation, reporting, and regulatory assessment of MIDD evidence.

The guidance does not prescribe specific modeling methodologies.

Instead, it establishes a harmonized framework that can be applied across various quantitative approaches.

The objective is to ensure that modeling evidence is scientifically credible, transparent, and appropriate for the regulatory decision it is intended to support.

Scope of the Guidance

The guideline applies to both current and emerging modeling methodologies.

Examples include:

• Population Pharmacokinetic (PopPK) Models
• Pharmacokinetic/Pharmacodynamic (PK/PD) Models
• Physiologically Based Pharmacokinetic (PBPK) Models
• Exposure-Response Models
• Model-Based Meta-Analysis (MBMA)
• Quantitative Systems Pharmacology (QSP) Models
• Disease Progression Models
• Artificial Intelligence (AI) Approaches
• Machine Learning (ML) Methods

The framework is intentionally broad to accommodate future scientific innovation.

The Six Core Elements of MIDD Evidence Assessment

At the center of ICH M15 is a structured evidence assessment framework.

1. Question of Interest

The Question of Interest defines the specific regulatory or development question that the model is intended to answer.

Examples include:

• Dose selection decisions
• Pediatric extrapolation strategies
• Labeling recommendations
• Clinical trial design optimization

A clearly defined question forms the foundation of the entire modeling strategy.

2. Context of Use

Context of Use describes how the model will be applied within the decision-making process.

It defines:

• Intended application
• Regulatory relevance
• Decision environment
• Supporting evidence requirements

The same model may require different evaluation standards depending on its intended use.

3. Model Influence

Model influence reflects the degree to which a decision depends on model outputs.

Higher influence generally means:

• Greater regulatory reliance
• Increased scrutiny
• More extensive evaluation requirements

The more critical the model's role, the greater the expectations for demonstrating credibility.

4. Consequence of Wrong Decision

This element evaluates the potential impact of an incorrect decision supported by the model.

Potential consequences may involve:

• Patient safety risks
• Reduced efficacy outcomes
• Clinical trial failures
• Regulatory setbacks

Higher consequences generally require stronger evidence supporting model performance.

5. Model Risk

Model risk is determined by combining:

• Model influence
• Consequence of wrong decision

This risk-based approach serves as a central principle of ICH M15.

The resulting risk level determines the depth of model evaluation necessary to establish confidence.

6. Model Impact

Model impact assesses how much the proposed MIDD approach deviates from existing regulatory standards or expectations.

High-impact applications may involve:

• Novel methodologies
• Innovative development approaches
• Reduced reliance on traditional clinical evidence

Higher impact generally requires more robust justification and documentation.

The Risk-Based Assessment Framework

One of the most significant contributions of ICH M15 is the formal adoption of a risk-based assessment strategy.

Core Principle

The level of model evaluation should be proportional to:

• Model influence
• Consequence of wrong decision
• Overall model risk

This approach helps ensure that regulatory expectations remain scientifically justified and practical.

Rather than applying identical standards to all models, evaluation efforts are tailored according to the importance of the decision being supported.

Regulatory Planning Expectations

The guidance strongly encourages proactive regulatory engagement.

Sponsors should:

• Define objectives early
• Establish model strategies prospectively
• Discuss MIDD approaches with regulators
• Align on evaluation expectations
• Document assumptions and methodologies

Early communication can reduce uncertainty and improve regulatory acceptance.

Increasingly, agencies view MIDD planning as an integral component of development strategy.

Model Evaluation Requirements

Model evaluation must demonstrate that the model is fit for its intended purpose.

ICH M15 emphasizes three core activities:

Verification

Verification confirms that the model has been implemented correctly.

This includes:

• Computational accuracy
• Coding integrity
• Reproducibility assessments

Validation

Validation evaluates whether the model adequately represents the intended biological, clinical, or pharmacological system.

Validation activities may involve:

• Predictive performance assessments
• Comparison with observed data
• External validation exercises

Applicability Assessment

Applicability assessment determines whether the model is appropriate for the specific decision context.

This includes evaluation of:

• Intended use
• Population relevance
• Data suitability
• Decision support capability

Technical Evaluation Expectations

The guideline outlines several important technical considerations.

Evaluation activities should address:

• Data quality and relevance
• Model assumptions
• Structural appropriateness
• Parameter uncertainty
• Robustness testing
• Sensitivity analyses
• Performance metrics
• Predictive capability
• External validation when appropriate

Evaluation rigor should remain proportional to model risk.

Documentation Requirements

ICH M15 places significant emphasis on transparent documentation.

Key documentation components include:

Model Analysis Plan (MAP)

The MAP should describe:

• Objectives
• Methodology
• Assumptions
• Planned analyses
• Evaluation criteria

Model Analysis Report (MAR)

The MAR documents:

• Results
• Findings
• Model performance
• Conclusions

MIDD Evidence Assessment Table

This structured assessment serves as a primary communication tool between sponsors and regulators.

Understanding the MIDD Evidence Assessment Table

The Evidence Assessment Table is a central feature of the new framework.

The table documents:

• Question of interest
• Context of use
• Model influence
• Consequence of wrong decision
• Model risk determination
• Model impact assessment
• Evaluation outcomes
• Final conclusions

The goal is to improve consistency, transparency, and regulatory review efficiency.

Submission Expectations

Regulatory submissions incorporating MIDD evidence should include comprehensive supporting materials.

Typical expectations include:

• Supporting datasets
• Analysis code
• Model files
• Evaluation results
• MAP documentation
• MAR documentation
• Evidence assessment tables
• Cross-references within submission modules

Transparency and reproducibility remain critical regulatory principles.

Emerging Trends in Model-Informed Drug Development

The future of drug development is becoming increasingly model-informed, data-driven, and predictive.

Why MIDD Readiness Is a Competitive Advantage

The most successful sponsors will not compete solely through scientific innovation.

They will increasingly compete through:

• Quantitative development capabilities
• Regulatory agility
• Evidence generation excellence
• Modeling expertise
• Data integration maturity
• Submission readiness

Organizations with mature MIDD programs can:

• Accelerate development timelines
• Improve regulatory interactions
• Reduce uncertainty
• Optimize trial design
• Strengthen decision-making confidence
• Support global regulatory submissions

How Maven Regulatory Solutions Supports MIDD Compliance

Our Expertise Includes

• MIDD strategy development
• PBPK and PK/PD regulatory support
• Regulatory submission planning
• MAP and MAR preparation
• Evidence assessment documentation
• Quantitative regulatory strategy
• Global submission support
• Regulatory intelligence monitoring

Why Companies Choose Maven

• Deep regulatory expertise
• Science-driven consulting approaches
• Global compliance experience
• End-to-end development support
• Scalable regulatory solutions
• Future-focused planning strategies

Conclusion

The ICH M15 guidance represents a landmark step toward global harmonization of Model-Informed Drug Development practices.

By establishing a structured, risk-based framework for planning, evaluating, documenting, and assessing MIDD evidence, regulators have created a clearer pathway for integrating quantitative evidence into regulatory decision-making.

Organizations that proactively invest in:

• MIDD strategy development
• Risk-based model evaluation
• Robust documentation systems
• Regulatory engagement planning
• Quantitative evidence generation

will be better positioned to navigate evolving regulatory expectations and accelerate successful drug development programs.

The strongest MIDD programs are no longer optional analytical exercises.

They are strategic assets supporting modern pharmaceutical innovation.

FAQ

1. What is ICH M15?

ICH M15 is a harmonized international guideline establishing principles for the generation, evaluation, reporting, and regulatory assessment of Model-Informed Drug Development evidence.

2. What is Model-Informed Drug Development (MIDD)?

MIDD uses modeling and simulation approaches to support drug development and regulatory decision-making.

3. Which modeling approaches are covered?

The guidance applies to PopPK, PK/PD, PBPK, exposure-response, MBMA, QSP, disease progression models, AI, ML, and other emerging methodologies.

4. What determines model risk?

Model risk is determined by combining model influence and the consequence of a wrong decision.

5. What documentation is required?

Sponsors should provide a Model Analysis Plan (MAP), Model Analysis Report (MAR), MIDD Evidence Assessment Table, supporting datasets, code, model files, and evaluation results.